3D Printed Drugs Market by Spritam (U.S. and Rest of World) and Other Drugs Potential Market by Scenario (Rapid Growth Scenario, Moderate Growth Scenario, and Low Growth Scenario) - Global Opportunity Analysis and Industry Forecast, 2017-2030

  • Report Number: 1008
  • Publish Date: 10-May-2018
  • Pages: 125
  • Tables: 24

Reports Overview

3D Printed Drugs Market are medications, which are designed by 3D printing technique to customize for the individuals in a safer and effective way. These drugs have unitary porous structures that readily disperse in the mouth, as a result of which these high-dose medicines need not to be swallowed intact. Thus, this form of medication is helpful to patients who often have swallowing difficulties, children, elderly, and those dealing with the complications of stroke, Alzheimers disease, head & neck tumors, and other neurological disorders. The first 3D printed drug to receive approval from the U.S. Food and Drug Administration (FDA) is Spritam (levetiracetam) tablets developed by Aprecia Pharmaceuticals.

Spritam is the only 3D printed drug which has received FDA approval. This drug was first available in the market in 2016, and can be used to treat epilepsy. The potential market for other 3D printed drugs (moderate growth scenario) is estimated to be $278 million in 2020, and would reach $522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030.

Surge in demand for instantaneous soluble drugs that can disperse easily in the mouth is the major factor that drives the growth of the global 3D printed drugs market. In addition, increase in prevalence of dysphagia, rise in usage of 3D printing technique in the medical & healthcare industries, increase in adoption of personalized drugs, and production of combination medicine boost the market growth.

However, adverse effect related to these drugs, usage of 3D printing to develop illegal drugs, and lack of government regulations for 3D printed products restrain the growth of the market. Conversely, rise in awareness pertaining to the advantages of these drugs, such as their instantaneous solubility, improvement in healthcare infrastructure, and technological advancements in developing countries are expected to provide numerous opportunities for the market growth.

Market Dynamics of 3D Printed Drugs Market

Segment Review

The global potential analysis of other 3D printed drugs market is analyzed based on forecast scenario such as rapid growth scenario, moderate growth scenario, and low growth scenario. In the rapid growth scenario, maximum percentage of total population affected by dysphagia is estimated to be treated in the first-year launch of 3D printed drugs in the market.

Snapshot of LAMEA 3D Printed Drugs Market

The major driver of the LAMEA other 3D printed drugs market include rise in prevalence of dysphagia. Brazilian Journal of Otorhinolaryngology reported that in 2017 approximately 65 million people were affected by dysphagia in Brazil, that is, around 35.9% of total population of Brazil. Thus, increasing number of people suffering from dysphagia and developing healthcare facilities are expected to fuel the market growth.

In addition, technological advancement in the region, increase in affordability, and rise in awareness towards 3D printing technique fuel the market growth. Moreover, increase in funds by government organizations to improve the healthcare infrastructure propels the growth of the 3D printed drugs market in LAMEA.

The key players profiled in this report include Aprecia Pharmaceuticals, GlaxoSmithKline Plc., Hewlett Packard Caribe, BV, LLC, 3D Printer Drug Machine, and FabRx Ltd.

The organizations engaged in the research of 3D printed drugs included in this report are UCL School of Pharmacy, University of Glasgow, University College London, The University of Nottingham, and National University of Singapore.

The other organizations in the value chain include University of Michigan, bo Akademi University, and University of Sheffield.

Key Benefits

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
  • The report provides information about the current and upcoming trends in the market from 2016 to 2023, which helps to determine the prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
  • Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the global market.

3D Printed Drugs Market Key Segments:

By Geography

  • U.S.
  • Rest of World

By Scenario

  • Low Growth Scenario
  • Moderate Growth Scenario
  • Rapid Growth Scenario

By Region

  • North America
    • U.S.
    • Rest of North America
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • Rest of LAMEA

Table Of Content

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS

Chapter: 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. 3D PRINTED DRUGS: AN OVERVIEW

3.2.1. Why 3D printed drugs?
3.2.2. Indications

3.2.2.1. Dysphagia: target population
3.2.2.2. Other indications

3.2.3. What to expect?

3.2.3.1. Customized dosage forms

3.2.3.1.1. Color
3.2.3.1.2. Flavor
3.2.3.1.3. Shape
3.2.3.1.4. Personalized medications

3.2.3.2. Release of complex drugs

3.2.4. 3D drug printing technologies

3.2.4.1. Inkjet printing
3.2.4.2. Direct-write
3.2.4.3. Zip dose
3.2.4.4. Thermal inkjet (TIJ) printing
3.2.4.5. Fused deposition modelling (FDM)
3.2.4.6. Powder bed printing
3.2.4.7. Stereolithography (SLA)

3.3. MARKET DYNAMICS

3.3.1. Drivers

3.3.1.1. High demand of instantaneous soluble tablets
3.3.1.2. Increasing prevalence of dysphagia
3.3.1.3. Growing usage of 3D printing
3.3.1.4. Increasing adoption of personalized drugs

3.3.2. Restraints

3.3.2.1. 3D printing could be used to print illegal drugs
3.3.2.2. Stringent government regulations for 3D printed products

3.3.3. Opportunities

3.3.3.1. Growing healthcare infrastructure and increase in healthcare investment in emerging nations
3.3.3.2. Rising awareness about the 3D printing technology

3.3.4. Impact analysis

Chapter: 4 SPRITAM: 3D PRINTED DRUGS MARKET

4.1. OVERVIEW

4.1.1. Key market trends
4.1.2. Growth factors and opportunities

4.2. MARKET SIZE AND FORECAST
4.3. BY GEOGRAPHY

4.3.1. U.S.

4.3.1.1. Key market trends
4.3.1.2. Growth factors and opportunities
4.3.1.3. Market size and forecast

4.3.2. Rest of World

4.3.2.1. Growth factors and opportunities
4.3.2.2. Market size and forecast

Chapter: 5 OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY SCENARIO

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. LOW GROWTH SCENARIO

5.2.1. Market size and forecast

5.3. MODERATE GROWTH SCENARIO

5.3.1. Market size and forecast

5.4. HIGH GROWTH SCENARIO

5.4.1. Market size and forecast

Chapter: 6 OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S.
6.2.5. Rest of North America

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. UK
6.3.5. Germany
6.3.6. France
6.3.7. Italy
6.3.8. Spain
6.3.9. Rest of Europe

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. Japan
6.4.5. China
6.4.6. Australia
6.4.7. Rest of Asia-Pacific

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil
6.5.5. Saudi Arabia
6.5.6. Rest of LAMEA

Chapter: 7 COMPANY PROFILES

7.1. APRECIA PHARMACEUTICALS COMPANY

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Key strategic moves and developments

7.2. FABRX LTD.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments

7.3. GLAXOSMITHKLINE PLC

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance

LIST OF TABLES

TABLE 1. LIST OF 3D PRINTED DRUGS DEVELOPED BY APRECIA PHARMACEUTICALS APPROVED BY FDA
TABLE 2. GLOBAL 3D PRINTED DRUGS MARKET FOR SPRITAM, BY GEOGRAPHY, 2017-2023 ($MILLION)
TABLE 3. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY SCENARIO, 2020-2030 ($MILLION)
TABLE 4. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY LOW GROWTH SCENARIO, BY REGION, 2020-2030, ($MILLION)
TABLE 5. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY MODERATE GROWTH SCENARIO, BY REGION, 2020-2030, ($MILLION)
TABLE 6. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY HIGH GROWTH SCENARIO, BY REGION, 2020-2030, ($MILLION)
TABLE 7. NORTH AMERICA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 8. NORTH AMERICA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 9. NORTH AMERICA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 10. EUROPE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 11. EUROPE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 12. EUROPE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 13. ASIA-PACIFIC OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 14. ASIA-PACIFIC OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 15. ASIA-PACIFIC OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 16. LAMEA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 17. LAMEA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 18. LAMEA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, HIGH GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 19. APRECIA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 20. APRECIA PHARMACEUTICALS: OPERATING SEGMENT
TABLE 21. FABRX: COMPANY SNAPSHOT
TABLE 22. FABRX: PRODUCT SEGMENT
TABLE 23. GSK: COMPANY SNAPSHOT
TABLE 24. GSK: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 1. PREVALENCE OF DYSPHAGIA ASSOCIATED WITH VARIOUS DIORDERS, 2008 (IN PERCENTAGE)
FIGURE 2. IMPACT ANALYSIS, 2017
FIGURE 3. U.S. 3D PRINTED DRUGS MARKET FOR SPRITAM, 2017-2023 ($MILLION)
FIGURE 4. REST OF WORLD 3D PRINTED DRUGS MARKET FOR SPRITAM, 2017-2023 ($MILLION)
FIGURE 5. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 6. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 7. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY HIGH GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 8. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, SHARE BY REGION, 2020 (%)
FIGURE 9. U.S. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 10. U.S. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 11. U.S. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 12. REST OF NORTH AMERICA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 13. REST OF NORTH AMERICA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 14. REST OF NORTH AMERICA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 15. UK OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 16. UK OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 17. UK OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 18. GERMANY OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 19. GERMANY OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 20. GERMANY OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 21. FRANCE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 22. FRANCE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 23. FRANCE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 24. ITALY OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 25. ITALY OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 26. ITALY OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 27. SPAIN OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 28. SPAIN OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 29. SPAIN OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 30. REST OF EUROPE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 31. REST OF EUROPE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 32. REST OF EUROPE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 33. JAPAN OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 34. JAPAN OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 35. JAPAN OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 36. CHINA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 37. CHINA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 38. CHINA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 39. AUSTRALIA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 40. AUSTRALIA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 41. AUSTRALIA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 42. REST OF ASIA-PACIFIC OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 43. REST OF ASIA-PACIFIC OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 44. REST OF ASIA-PACIFIC OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 45. BRAZIL OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 46. BRAZIL OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 47. BRAZIL OTHER 3D PRINTED DRUGS POTENTIAL MARKET, HIGH GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 48. SAUDI ARABIA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 49. SAUDI ARABIA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 50. SAUDI ARABIA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, HIGH GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 51. REST OF LAMEA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 52. REST OF LAMEA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 53. REST OF LAMEA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, HIGH GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 54. GSK: REVENUE, 2014-2016 ($MILLION)
FIGURE 55. GSK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 56. GSK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

3D Printed Drugs Market are medications, which are designed by 3D printing technique to customize for the individuals in a safer and effective way. These drugs have unitary porous structures that readily disperse in the mouth, as a result of which these high-dose medicines need not to be swallowed intact. Thus, this form of medication is helpful to patients who often have swallowing difficulties, children, elderly, and those dealing with the complications of stroke, Alzheimers disease, head & neck tumors, and other neurological disorders. The first 3D printed drug to receive approval from the U.S. Food and Drug Administration (FDA) is Spritam (levetiracetam) tablets developed by Aprecia Pharmaceuticals.

There are no reviews yet.

Be the first to review “3D Printed Drugs Market Report 2018”